Rafael Holdings Inc(RFL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.68 | Insider Own | 32.61% | Shs Outstand | 51.2M | Perf Week | -5.98% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 35.0M | Perf Month | 22.92% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | - | Inst Own | 7.5% | Short Float | 1.14% | Perf Quarter | 32.58% |
| Income | -0.03B | P/S | 125.26 | EPS this Y | - | Inst Trans | 4.75% | Short Ratio | 2.01 | Perf Half Y | 57.33% |
| Sales | 0.00B | P/B | 1.63 | EPS next 5Y | - | ROA | -32.54% | Short Interest | 0.40M | Perf YTD | 100% |
| Book/sh | 1.45 | P/C | 4.02 | EPS past 3/5Y | 44.95% -9.76% | ROE | -41.74% | 52W High | -40.4% ($3.96) | Perf Year | 77.44% |
| Cash/sh | 0.59 | P/FCF | - | Sales past 3/5Y | 30.78% -28.51% | ROIC | -43.18% | 52W Low | 110.71% ($1.12) | Perf 3Y | 8.39% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.75% | Gross Margin | 74.39% | Volatility(W/M) | 10.48% 10.29% | Perf 5Y | -93.27% |
| Dividend TTM | - | EV/Sales | 100.29 | Sales Y/Y TTM | 33.88% | Oper. Margin | -3717.24% | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.14 | EPS Q/Q | 55.81% | Profit Margin | -3321.73% | RSI (14) | 53.69 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.16 | Sales Q/Q | -50.55% | SMA20 | 5.38% ($2.24) | Beta | 0.3 | Target Price | - |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/3/16 | SMA50 | 5.06% ($2.25) | Rel Volume | 0.92 | Prev Close | $2.29 |
| Employees | 23 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 45.95% ($1.62) | Avg Volume(3M) | 0.20M | Price | $2.36 |
| IPO | 2018/3/27 | Option/Short | Yes/Yes | Trades | 500 | Volume | 182,359 | Change | 3.06% |
Company
RFL is a Real Estate sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Raphael Holdings is a diversified holding company established in 2017 and headquartered in New Jersey, USA. The company simultaneously holds commercial real estate assets and invests in equity stakes in clinical-stage pharmaceutical companies, and is organized into three business segments: Healthcare, Infusion Technology, and Real Estate. It is a micro-cap holding company that combines the stable cash flow from real estate rental income with the growth potential of rare disease and oncology drug candidates.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
RFL has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Would have changed by +8.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 7.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
DFAS 0.00%
DFAT 0.00%
DFAC 0.00%
VTI 0.00%It ranks #4 in the industry
Based on market cap of $123M.
RFL $123M PER -
CBRE $40B PER 31.6
BEKE $18B PER 27.5
JLL $16B PER 16.4
FAQ
What kind of company is RFL?
RFL belongs to the Real Estate sector and operates in the Real Estate Services industry.
What is the market cap of RFL?
The market cap of RFL is approximately $123M, ranking 4,440 within its sector.
What is the 52-week high and low for RFL?
RFL has recorded a 52-week high of $3.96 and a low of $1.12.
